Compare ONCY & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONCY | ACOG |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | Canada | Canada |
| Employees | N/A | 57 |
| Industry | Pharmaceuticals and Biotechnology | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.0M | 110.4M |
| IPO Year | 2002 | N/A |
| Metric | ONCY | ACOG |
|---|---|---|
| Price | $0.85 | $5.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $7.33 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 800.6K | 40.2K |
| Earning Date | 05-13-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $146.05 |
| Revenue Next Year | N/A | $127.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $3.75 |
| 52 Week High | $1.51 | $10.88 |
| Indicator | ONCY | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 44.18 |
| Support Level | $0.79 | $5.16 |
| Resistance Level | $1.32 | $6.52 |
| Average True Range (ATR) | 0.06 | 0.38 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 25.73 | 40.91 |
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.